Gene editing was supposed to be clean. The patent fight wasnt.
For fourteen years, CRISPR has moved from a breakthrough scientific idea to a platform technology that promises cures, not just therapies. Investors backed the platform. Patients waited f…
Stop Tracking Drug Patents. Start Tracking Who Controls Them.
Drug patenting has long been treated like the scoreboard of pharmaceutical strategy. If a patent expires, everyone watches the clock. If a court decision lands, the market reacts. But the re…
Stop Tracking Drug Patents. Start Tracking Who Controls Them. Read Post »
AI Cant Be Named as an Inventor on Drug PatentsUntil Congress Says Otherwise
What do drug developers, patent lawyers, and AI builders have in common right now? A growing mismatch between whats technologically possible and what the patent system legally…
No AI Has Ever Been Named Inventor on a Drug Patent. Here’s the Rule That Guarantees It. Read Post »
If youve ever searched Google Patents for a drug name and thought, Greatthis will show me everything that matters, youre not alone.
But heres the problem: Google Patents wasnt built for pharma workflows. It was built for broad, general-purpose discover…
Google Patents Wasnt Built for PharmaHeres What It Misses Every Time You Search a Drug Name
Most people search Google the way they search for truth: type a name, hit enter, and assume the system will surface what matters.
But if youre in pharmaregula…
Manual cross-referencing is quietly becoming one of the most expensive line items in modern patent strategyespecially when its hiding behind free data.
Lets talk about the free patent database problem. Not the absence of cost, but the cost of time, ris…
The Free Patent Database Costing Your Team Thousands an Hour in Manual Cross-Referencing Read Post »
A spreadsheet of patent expirations doesnt make a strategyit creates a liability with a due date.
Heres the uncomfortable truth: in pharma, knowing what expires when is necessary, but its never sufficient. A static list of dates can feel like controlun…
A Three-Week Analyst Report That Shouldve Been Three Hours: Heres the Bottleneckand How to Fix It
In most industries, time is the cheapestand most underpricedasset you can manage.
So when a seemingly straightforward deliverable stretches from three hou…
Regulatory quarterly review doesnt just miss patentcompanies miss the timing. Thats why they keep losing NCE-1 dates.
Every year, the same pattern repeats across pharma: companies rely on the quarterly review process as a backstop, then act surprised w…
Stop Searching Patents. Start Asking Them Questions.
If youve ever done patent diligence by keyword searching a database and exporting a spreadsheet, youre not alone. But you might be missing the most important part of the exercise: interpretation.
Bec…
Stop Searching Patents. Start Asking Them Questions. Read Post »
Get new actionable insights and updates from BiotechBlog
